Walmsley Under Pressure Over GSK’s Strategy
Activist Investor Preparing To Pounce
GSK’s share price is down by 15% since Walmsley took over as CEO, but major investors are said to be resisting calls for a radical re-think in its strategy.
You may also be interested in...
J&J’s Consumer Health Spinout Plan Surprises, But Seen As Sensible
Analysts say the pharma’s plan would separate out a unit with less growth and lower margins – and some predict a further breakup of the pharma and medical device units.
GSK Has Big Ambitions In Vaccines, With An Eye On Blockbuster Opportunities
The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast episode of Five Must-Know Things, hear about GSK coming under pressure from investors; BMS focusing on a promising oncology target in a new deal; Sanofi’s COVID-19 vaccine challenges; China's progress with mRNA coronavirus vaccines; and new headwinds for Pfizer’s Ibrance.